Sunshine Biopharma Q2 net loss narrows 11.67% to $1.56 million; revenue slips 1.6% to $9.26 million

• Sunshine Biopharma posted a net loss of $1.56 million, or $1.15 per share, in the quarter ended June 30, 2026.
• Revenue slipped 1.6% to $9.26 million from a year earlier, due to distribution agreements ending Dec. 31, 2025.
• Gross profit fell to $2.43 million, cutting gross margin by 10.2 percentage points to 26.2% on higher costs.
• Operating loss narrowed to $1.61 million as general and administrative expenses dropped to $4.04 million.
• Cash and cash equivalents were $13.75 million at June 30, 2026; it forecasts funding for the next 27 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sunshine Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-006340), on August 13, 2026, and is solely responsible for the information contained therein.